Literature DB >> 8322843

Lipoprotein glomerulopathy. Report of a normolipidemic case and review of the literature.

T Saito1, H Sato, S Oikawa, K Kudo, I Kurihara, K Nakayama, K Abe, K Yoshinaga, H Sakaguchi.   

Abstract

Lipoprotein glomerulopathy is a disease characterized by intraglomerular lipoprotein thrombi and abnormal lipid metabolism similar to type III hyperlipoproteinemia. Recently, glomerular lesions compatible with lipoprotein glomerulopathy were found in a 38-year-old man. In this case, plasma apolipoprotein (apo) E level was elevated, and the apo E isoform was heterozygous E2/3, similar to most of the reported cases of lipoprotein glomerulopathy. However, the plasma levels of triglyceride and total cholesterol were within their respective normal ranges. Review in 11 cases revealed that lipoprotein glomerulopathy was not always associated with hyperlipidemia, and that apo E abnormality was always recognized. These findings suggest that lipoprotein thrombi associated with lipoprotein glomerulopathy are not induced via systemic hyperlipidemia but may be formed by intraglomerular accumulation of lipoprotein composed of abnormal apo E.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8322843     DOI: 10.1159/000168591

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  7 in total

1.  Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice.

Authors:  Atsunori Ishimura; Maho Watanabe; Hitoshi Nakashima; Kenji Ito; Katsuhisa Miyake; Shizue Mochizuki; Yasushi Ishigaki; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2009-05-21       Impact factor: 2.801

2.  Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.

Authors:  Boxun Luo; Fengxian Huang; Qicai Liu; Xiaoyan Li; Wenfang Chen; Shu-Feng Zhou; Xueqing Yu
Journal:  Am J Nephrol       Date:  2007-11-29       Impact factor: 3.754

3.  Long-term outcome of kidney transplantation in a patient with coexisting lipoprotein glomerulopathy and fibrillary glomerulonephritis.

Authors:  Chi Yuen Cheung; Angel O K Chan; Gordon P T Chan; Heidi Y P Iu; Chi Chung Shek; Ka Foon Chau
Journal:  Clin Kidney J       Date:  2014-06-17

Review 4.  Apolipoprotein E gene variants on the risk of end stage renal disease.

Authors:  Cheng Xue; Wei Nie; Dan Tang; Lujiang Yi; Changlin Mei
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

5.  Macrophage Infiltration into the Glomeruli in Lipoprotein Glomerulopathy.

Authors:  Satoshi Takasaki; Kunihiko Maeda; Kensuke Joh; Shu Yamakage; Sachiko Fukase; Toshiyuki Takahashi; Masayuki Suzuki; Akira Matsunaga; Takao Saito
Journal:  Case Rep Nephrol Dial       Date:  2015-12-15

6.  Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2.

Authors:  Megumu Fukunaga; Kiyotaka Nagahama; Michiko Aoki; Akira Shimizu; Shigeo Hara; Akira Matsunaga; Eri Muso; Takao Saito
Journal:  Case Rep Nephrol Dial       Date:  2018-03-20

7.  The Novel Apolipoprotein E Mutation ApoE Chengdu (c.518T>C, p.L173P) in a Chinese Patient with Lipoprotein Glomerulopathy.

Authors:  Hongyan Wu; Yuan Yang; Zhangxue Hu
Journal:  J Atheroscler Thromb       Date:  2018-02-02       Impact factor: 4.928

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.